Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Supernus Pharmaceuticals (SUPN)

Supernus terminates UBS credit line ahead of Indivior combination

Neutral Impact 2 of 5 financing

Supernus Pharmaceuticals terminated its uncommitted UBS revolving credit line on October 20, 2026, in connection with its planned business combination with Indivior Pharmaceuticals and a new senior secured credit facility for the combined company. The company reported no outstanding borrowings and no early termination penalties, so the termination itself has no direct financial cost disclosed in the filing.

Key points

  • Terminated UBS Credit Line Agreement dated February 8, 2023, with UBS Bank USA on October 20, 2026
  • No advances, letters of credit or other borrowings were outstanding at termination
  • No early termination penalties were incurred; the Bank's security interests in the collateral were released
  • Termination tied to the pending combination with Indivior Pharmaceuticals under a merger agreement dated August 1, 2026

The filing

CompanySupernus Pharmaceuticals (SUPN)
Form8-K, current report
Filed with the SECOct 26, 2026, 4:41 PM ET
Accession number0001356576-26-000045

Items reported: 1.02 Termination of Material Agreement

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.